Search

Your search keyword '"Bierzynska A"' showing total 209 results

Search Constraints

Start Over You searched for: Author "Bierzynska A" Remove constraint Author: "Bierzynska A"
209 results on '"Bierzynska A"'

Search Results

2. Rare heterozygous variants in paediatric steroid resistant nephrotic syndrome – a population-based analysis of their significance

3. Multivariate canonical correlation analysis identifies additional genetic variants for chronic kidney disease

5. De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis.

6. Exploring the relevance of NUP93 variants in steroid-resistant nephrotic syndrome using next generation sequencing and a fly kidney model

7. Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

8. A critical re-analysis of cases of post-transplantation recurrence in genetic nephrotic syndrome

9. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

10. National Unified Renal Translational Research Enterprise: Idiopathic Nephrotic Syndrome (NURTuRE-INS) study.

11. Investigating the genotype-phenotype correlations in paediatric steroid resistant nephrotic syndrome patients

12. A role for OCRL in glomerular function and disease

13. Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria(European Journal of Human Genetics, (2021), 29, 8, (1186-1197), 10.1038/s41431-021-00858-1)

14. Whole-genome sequencing of patients with rare diseases in a national health system.

16. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption

17. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management

18. Shared genetic risk across different presentations of gene test–negative idiopathic nephrotic syndrome

19. Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances

20. No Risk, No Differences. Neural Correlates of Temperamental Traits Revealed Using Naturalistic fMRI Method

21. FAT1 mutations cause a glomerulotubular nephropathy

22. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome

23. Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

24. Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

25. Correction: Guidelines for Genetic Testing and Management of Alport Syndrome

26. Shared genetic risk across different presentations of gene test–negative idiopathic nephrotic syndrome

27. Recent advances in understanding and treating nephrotic syndrome [version 1; referees: 2 approved]

28. Exploring the relevance of NUP93 variants in steroid-resistant nephrotic syndrome using next generation sequencing and a fly kidney model

29. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements

30. Guidelines for genetic testing and management of Alport syndrome

31. A Rare Autosomal Dominant Variant in Regulator of Calcineurin Type 1 (RCAN1) Gene Confers Enhanced Calcineurin Activity and May Cause FSGS

32. De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis

34. Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease

36. Response to First Course of Intensified Immunosuppression in Genetically Stratified Steroid Resistant Nephrotic Syndrome

37. CYTOKINESIS-BLOCK MICRONUCLEUS ASSAY IN HUMAN GLIOMA CELLS EXPOSED TO RADIATION

38. Guidelines for Genetic Testing and Management of Alport Syndrome

39. Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

40. Podocyte Bioenergetics in the Development of Diabetic Nephropathy: The Role of Mitochondria

42. Guidelines for Genetic Testing and Management of Alport Syndrome

43. Whole-genome sequencing of patients with rare diseases in a national health system

44. Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2

45. TBC1D8B Loss-of-Function Mutations Lead to X-Linked Nephrotic Syndrome via Defective Trafficking Pathways

46. A Rare Autosomal Dominant Variant in Regulator of Calcineurin Type 1 (RCAN1) Gene Confers Enhanced Calcineurin Activity and May Cause FSGS

47. Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension

48. A Rare Autosomal Dominant Variant in Regulator of Calcineurin Type 1 (

49. Publisher Correction:Whole-genome sequencing of a sporadic primary immunodeficiency cohort (Nature, (2020), 583, 7814, (90-95), 10.1038/s41586-020-2265-1)

50. MO075DNA METHYLATION AND RESPONSE TO STEROIDS IN CHILDREN WITH NEPHROTIC SYNDROME

Catalog

Books, media, physical & digital resources